A5004623555- Head and Neck Cancer Studies
- Head and Neck Surgical Oncology
- Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Oral health in cancer treatment
- Lung Cancer Research Studies
- Nutrition and Health in Aging
- Advanced Radiotherapy Techniques
- Radiopharmaceutical Chemistry and Applications
- Inflammatory Bowel Disease
- Management of metastatic bone disease
- Medical Imaging Techniques and Applications
- Tracheal and airway disorders
- Salivary Gland Tumors Diagnosis and Treatment
- Frailty in Older Adults
- Breast Cancer Treatment Studies
- Cervical Cancer and HPV Research
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Pain Mechanisms and Treatments
- Cancer Immunotherapy and Biomarkers
- Reconstructive Surgery and Microvascular Techniques
- Spinal Fractures and Fixation Techniques
- Microscopic Colitis
- Lung Cancer Diagnosis and Treatment
Institut Català d'Oncologia
2015-2025
Virginia Tech
2021-2024
Duran i Reynals Hospital
2015-2024
New York Proton Center
2022-2023
Carilion Clinic
2022
Universitat de Barcelona
2016-2021
Institut d'Investigació Biomédica de Bellvitge
2012-2021
Bellvitge University Hospital
2015-2021
Pomona College
2020
University of Pennsylvania
2017-2019
The benefits of radiotherapy and cetuximab have encouraged evaluation after radiotherapy. aims this study were to preclinically evaluate the efficacy maintenance eventually determine its mechanisms action.The A431 human carcinoma cell line was treated in culture with fractionated cetuximab. surviving cells injected s.c. into nude mice mimic microscopic residual disease. animals randomized receive either or saline solution. Tumor growth, proliferation (Ki-67), microvessel density (MVD),...
To examine the relationship between polymorphisms of epidermal growth factor receptor (EGFR) pathway and toxicity in head neck squamous cell carcinoma (HNSCC) patients treated with cetuximab. Multicenter, retrospective, observational pilot study which included 110 histologically-confirmed human papillomavirus (HPV) negative HNSCC locally advanced stages (III-IVA-B) who were chemotherapy radiotherapy plus cetuximab 2003 2013. Genetic analyses for single nucleotide (SNP) genes EGFR, CCDN1,...
Background: Anti-epithermal-growth-factor-receptor (EGFR) therapies in combination with radiotherapy are being studied on de-escalation clinical trials for HPV-related oropharyngeal cancer (OPC) patients. The HPV16-E5 oncoprotein increases recycling of activated EGFR to the cell surface, enhancing factor signal transduction. Our aim was evaluate viral oncogene expression as well and phosphorylated-EGFR (pEGFR), protein levels biomarkers outcome a retrospective cohort OPC Methods:...
Multidisciplinary teams (MDT) aid the diagnosis and management of patients with inflammatory bowel disease (IBD) improve patient outcomes. The direct impact a gastrointestinal expert pathologist on MDT care IBD is unknown.
Abstract Purpose This study aimed to examine health-related quality of life (HRQoL) in head and neck cancer patients at 1 5 years after successful treatment their tumors, explore the usefulness 2 instruments for assessing need dental care services. Methods cross-sectional pilot included 20 adult with who completed Functional Assessment Cancer Therapy-Head Neck (FACT H&N) Symptom Index European Organization Research Treatment Quality Life Head Module (EORTC QLQ-H&N43) treatment....
6001 Background: CetRT has not been compared with CRT after ICT in phase III. Objective: To compare the impact on overall survival of vs. a Phase III randomized controlled clinical trial non-inferiority design to CRT. Response Rate (RR), loco-regional control (LRC) and toxicity both arms were considered secondary objectives. Methods: Pts LAUHNC, ECOG 0-1, 18-72 years old, measurable disease, adequate renal liver function, received standard DCF G-CSF. After at least 2 cycles (range 2-3), pts...
6015 Background: TPF combination is the new standard IC. Adding cetuximab to PF chemotherapy superior alone in metastatic disease. We incorporated into IC with and subsequent radiotherapy (RT) unresectable SCCHN. Methods: Phase II trial conducted 7 Spanish hospitals. Previously untreated pts aged 18–70 yrs, ECOG PS 0–1 SCCHN were eligible. Induction comprised T 75mg/m 2 day 1, P F 750mg/m days 1–5, 250mg/m 8, 15 (initial dose 400mg/m on cycle (C) 1), repeated every 21 x 4 C, prophylactic...
5534 Background: Cetuximab combined with RT is a treatment option for locally advanced head and neck cancer, especially oropharyngeal tumors. The objectives of this prospective, randomized, multicenter, phase II trial were to evaluate the efficacy safety cetuximab maintenance therapy following definitive concomitant in pts cancer. Methods: Main eligibility criteria: >18 yrs old, stage III-IVM0 squamous Group A received boost (69.9Gy 28 days) + (400 mg/m2 1 wk before 250 mg/m2/wk during RT)....
Skin toxicity is the most common adverse event associated with use of EGFR inhibitors. Radiation dermatitis occurs to some degree in patients who receive radiotherapy, either alone or combination The effects both toxicities might be additive because irradiated skin zone squamous cell cancer head and neck (SCCHN) same area which inhibitor-related acne-like rash more common. This article summarizes principal issues discussed during a symposium that took place Madrid January 2009, management...
Abstract Background The purpose of this study was to describe the results and complications primary site salvage surgery after head neck squamous cell carcinoma (HNSCC) treated with bioradiotherapy. Methods We conducted a retrospective chart review 268 patients bioradiotherapy between March 2006 December 2013 at Hospital Universitari de Bellvitge‐ICO. Results Fifty‐nine developed local recurrence or had residual disease 1‐year 3‐year overall survival 47% 15.4%, respectively. Salvage feasible...
6007 Background: Severe Oral Mucositis (SOM) is one of the most significant adverse events (AE) in H&N cancer patients undergoing concurrent chemo/bio-radiotherapy. The objective trial to evaluate safety and efficacy melatonin (MLT) oral gel prevention treatment mucositis (OM) patients. Methods: Multicenter, prospective, randomized, double-blind, placebo-controlled study. Eligible were randomly assigned (1:1 ratio) receive 3% MLT or matching placebo (PLC) gel. Patients received once daily (5...